Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.2370
+0.0024 (1.02%)
At close: Feb 2, 2026, 4:00 PM EST
0.2370
0.00 (0.00%)
Pre-market: Feb 3, 2026, 5:19 AM EST

Akari Therapeutics, Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-15.77-19.79-10.01-17.75-17.42-17.08
Depreciation & Amortization
00.010000.01
Asset Writedown & Restructuring Costs
5.18-----
Stock-Based Compensation
3.682.251.150.740.310.33
Other Operating Activities
-3.85-1.56-6.71-5.320.24-0.15
Change in Accounts Payable
0.535.22-0.94-0.88-0.24-0.25
Change in Other Net Operating Assets
0.591.320.071.7-1.740.19
Operating Cash Flow
-9.65-12.55-16.43-21.5-18.85-16.95
Cash Acquisitions
0.380.38----
Investing Cash Flow
0.380.38----
Short-Term Debt Issued
-1.03----
Total Debt Issued
2.131.03----
Short-Term Debt Repaid
--1.86----
Total Debt Repaid
-1.9-1.86----
Net Debt Issued (Repaid)
0.22-0.83----
Issuance of Common Stock
9.0111.827.0225.2914.2925.07
Other Financing Activities
0.33-----
Financing Cash Flow
9.5710.997.0225.2914.2925.07
Foreign Exchange Rate Adjustments
0-00.010.11-0.140.2
Net Cash Flow
0.3-1.19-9.413.89-4.698.32
Free Cash Flow
-9.65-12.55-16.43-21.5-18.85-16.95
Free Cash Flow Per Share
-0.35-1.05-3.36-6.89-8.78-10.73
Levered Free Cash Flow
0.283.91-16.74-6.04-11.31-11.96
Unlevered Free Cash Flow
0.54.06-16.74-6.04-11.31-11.96
Change in Working Capital
1.126.54-0.870.82-1.98-0.06
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q